Orange Book product · Generic (ANDA)
CEFDINIR
CEFDINIR
At a glance
May 31, 2006
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 31, 2006
20 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
CEFDINIR
Strength
125MG/5ML
Dosage form
FOR SUSPENSION
Route
ORAL
TE code
AB
Application
ANDA 065259
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of CEFDINIR
- 1997OMNICEFBrand (NDA)
NDA 050739 · ABBVIE
- 1997OMNICEFBrand (NDA)
NDA 050749 · ABBVIE
- 2021CEFDINIRGeneric (ANDA)
ANDA 210220 · ALKEM LABS LTD
- 2021CEFDINIRGeneric (ANDA)
ANDA 210534 · ALKEM LABS LTD
- 2008CEFDINIRGeneric (ANDA)
ANDA 065434 · AUROBINDO PHARMA
- 2007CEFDINIRGeneric (ANDA)
ANDA 065473 · AUROBINDO PHARMA
- 2007CEFDINIRGeneric (ANDA)
ANDA 065418 · ANDA REPOSITORY
- 2007CEFDINIRGeneric (ANDA)
ANDA 065429 · ANDA REPOSITORY
- 2007CEFDINIRGeneric (ANDA)
ANDA 065368 · TEVA PHARMS
- 2007CEFDINIRGeneric (ANDA)
ANDA 065332 · TEVA PHARMS
- 2007CEFDINIRGeneric (ANDA)
ANDA 065330 · CHARTWELL RX
- 2007CEFDINIRGeneric (ANDA)
ANDA 065337 · CHARTWELL RX
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
